[{"indications": "Indications\u00a0erectile dysfunction; pulmonary hypertension\r\n(section 2.5.1)", "name": "TADALAFIL - PHOSPHODIESTERASE TYPE-5 INHIBITORS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "7 Obstetrics, gynaecology, and urinary-tract disorders", "7.4 Drugs for genito-urinary disorders", "7.4.5 Drugs for erectile dysfunction", "Phosphodiesterase type-5 inhibitors", "TADALAFIL"], "cautions": "Cautions\u00a0\n(From Phosphodiesterase type-5 inhibitors: British National Formulary)\nCautions\u00a0Sildenafil, tadalafil, and vardenafil should be used with caution in cardiovascular disease, left ventricular outflow obstruction, anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie\u2019s disease), and in those with a predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia). Concomitant treatment with a phosphodiesterase type-5 inhibitor and an alpha-blocker (section 2.5.4 and section 7.4.1) can increase the risk of postural hypotension\u2014initiate treatment with a phosphodiesterase type-5 inhibitor (at a low dose) only once the patient is stable on the alpha-blocker; see also interactions: Appendix 1 (sildenafil, tadalafil, vardenafil).; interactions: Appendix 1 (tadalafil)", "side-effects": "Side-effects\u00a0\n(From Phosphodiesterase type-5 inhibitors: British National Formulary)\nThe side-effects of sildenafil, tadalafil, and vardenafil include dyspepsia, nausea, vomiting, headache (including migraine), flushing, dizziness, myalgia, back pain, visual disturbances (non-arteritic anterior ischaemic optic neuropathy has been reported\u2014stop drug if sudden visual impairment occurs), and nasal congestion. Less common side-effects include painful red eyes, palpitation, tachycardia, hypotension, hypertension, epistaxis. Other side-effects reported rarely include syncope, hypersensitivity reactions (including rash, facial oedema, and Stevens-Johnson syndrome), and priapism. Serious cardiovascular events (including arrhythmia, unstable angina, and myocardial infarction), seizures, sudden hearing loss (discontinue drug and seek medical advice), and retinal vascular occlusion have also been reported. ; also\r\nincreased sweating, abdominal pain, and transient amnesia reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119673.htm", "doses": ["adult over 18 years, initially\r\n10\u00a0mg at least 30 minutes before sexual activity, subsequent doses\r\nadjusted according to response, up to 20\u00a0mg as a single dose; max.\r\n1 dose in 24 hours (but daily dose of 10\u201320\u00a0mg not recommended); for\r\npatients who anticipate sexual activity at least twice weekly, 5\u00a0mg\r\nonce daily can be taken, reduced to 2.5\u00a0mg once daily according to\r\nresponse", "Effect of intermittent dosing may persist\r\nfor longer than 24 hours"]}, {"indications": "Indications\u00a0erectile dysfunction; pulmonary hypertension\r\n(section 2.5.1)", "name": "TADALAFIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "7 Obstetrics, gynaecology, and urinary-tract disorders", "7.4 Drugs for genito-urinary disorders", "7.4.5 Drugs for erectile dysfunction", "Phosphodiesterase type-5 inhibitors", "TADALAFIL"], "cautions": "Cautions\u00a0\n(From Phosphodiesterase type-5 inhibitors: British National Formulary)\nCautions\u00a0Sildenafil, tadalafil, and vardenafil should be used with caution in cardiovascular disease, left ventricular outflow obstruction, anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie\u2019s disease), and in those with a predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia). Concomitant treatment with a phosphodiesterase type-5 inhibitor and an alpha-blocker (section 2.5.4 and section 7.4.1) can increase the risk of postural hypotension\u2014initiate treatment with a phosphodiesterase type-5 inhibitor (at a low dose) only once the patient is stable on the alpha-blocker; see also interactions: Appendix 1 (sildenafil, tadalafil, vardenafil).; interactions: Appendix 1 (tadalafil)", "side-effects": "Side-effects\u00a0\n(From Phosphodiesterase type-5 inhibitors: British National Formulary)\nThe side-effects of sildenafil, tadalafil, and vardenafil include dyspepsia, nausea, vomiting, headache (including migraine), flushing, dizziness, myalgia, back pain, visual disturbances (non-arteritic anterior ischaemic optic neuropathy has been reported\u2014stop drug if sudden visual impairment occurs), and nasal congestion. Less common side-effects include painful red eyes, palpitation, tachycardia, hypotension, hypertension, epistaxis. Other side-effects reported rarely include syncope, hypersensitivity reactions (including rash, facial oedema, and Stevens-Johnson syndrome), and priapism. Serious cardiovascular events (including arrhythmia, unstable angina, and myocardial infarction), seizures, sudden hearing loss (discontinue drug and seek medical advice), and retinal vascular occlusion have also been reported. ; also\r\nincreased sweating, abdominal pain, and transient amnesia reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119673.htm", "doses": ["adult over 18 years, initially\r\n10\u00a0mg at least 30 minutes before sexual activity, subsequent doses\r\nadjusted according to response, up to 20\u00a0mg as a single dose; max.\r\n1 dose in 24 hours (but daily dose of 10\u201320\u00a0mg not recommended); for\r\npatients who anticipate sexual activity at least twice weekly, 5\u00a0mg\r\nonce daily can be taken, reduced to 2.5\u00a0mg once daily according to\r\nresponse", "Effect of intermittent dosing may persist\r\nfor longer than 24 hours"]}, {"indications": "Indications\u00a0pulmonary arterial hypertension;\r\nerectile dysfunction (section 7.4.5)", "name": "TADALAFIL - VASODILATOR ANTIHYPERTENSIVE DRUGS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.1 Vasodilator antihypertensive drugs", "TADALAFIL"], "cautions": "Cautions\u00a0hypotension (avoid if systolic blood pressure below 90\u00a0mmHg); aortic and mitral\r\nvalve disease; pericardial constriction; congestive cardiomyopathy; left ventricular dysfunction; life-threatening\r\narrhythmias; coronary artery disease; uncontrolled hypertension; pulmonary veno-occlusive disease; predisposition\r\nto priapism; anatomical deformation of\r\nthe penis; hereditary degenerative retinal\r\ndisorders; interactions: Appendix 1\r\n(tadalafil)", "side-effects": "Side-effects\u00a0nausea, vomiting, dyspepsia, gastro-oesophageal\r\nreflux, chest pain, palpitation, flushing, hypotension, nasopharyngitis,\r\nepistaxis, headache, myalgia, back and limb pain, increased uterine\r\nbleeding, blurred vision, facial oedema, rash; less commonly tachycardia, hypertension, seizures, amnesia, priapism, hyperhidrosis; also reported unstable angina, arrhythmia, myocardial infarction,\r\nstroke, hearing loss, non-arteritic anterior ischaemic optic neuropathy,\r\nretinal vascular occlusion, visual field defect, Stevens-Johnson syndrome ", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213711.htm", "doses": ["adult over 18 years, 40\u00a0mg\r\nonce daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid"}]